Can semaglutide (Ozempic) cause retinal hemorrhage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Ozempic Cause Retinal Hemorrhage?

Yes, Ozempic (semaglutide) is associated with diabetic retinopathy complications including retinal hemorrhage, particularly in patients with pre-existing diabetic retinopathy or those experiencing rapid glucose reduction. The FDA label explicitly warns about diabetic retinopathy complications, and recent evidence confirms associations with retinal hemorrhage among other retinal adverse events 1.

Understanding the Risk

The mechanism appears dual:

  • Rapid glucose reduction effect: When A1C drops quickly (a known effect of semaglutide), temporary worsening of diabetic retinopathy can occur—a phenomenon previously documented with intensive insulin therapy 2, 3
  • Direct retinal complications: The SUSTAIN 6 trial demonstrated that 3.0% of semaglutide-treated patients experienced diabetic retinopathy complications versus 1.8% on placebo. The absolute risk was substantially higher (8.2% vs 5.2%) in patients with baseline diabetic retinopathy 1

Recent pharmacovigilance data strengthens these concerns. A 2025 global analysis of over 76,000 cases found semaglutide significantly associated with retinal/vitreous hemorrhage (ROR = 2.44-5.89 in FAERS, ROR = 5.49-20.91 in VigiBase compared to metformin) 4. Another 2025 study specifically identified retinal hemorrhage as more frequently reported with subcutaneous semaglutide formulations 5.

Clinical Algorithm for Safe Use

Before initiating Ozempic:

  1. Assess retinopathy status - Obtain dilated comprehensive eye examination if not done within past year 2
  2. Identify high-risk patients: Those with known diabetic retinopathy, especially proliferative disease, or baseline A1C >10% with long diabetes duration
  3. Document baseline A1C to anticipate degree of glucose reduction

During treatment:

  • Monitor vision changes actively - Instruct patients to report any visual changes immediately 1
  • Increase ophthalmology surveillance - Patients with baseline retinopathy require more frequent eye exams (at minimum annually, potentially every 3-6 months if retinopathy present) 2
  • Titrate gradually in high-risk patients to minimize rapid A1C drops, though this must be balanced against cardiovascular benefits

If retinopathy worsens:

The 2024 ADA guidelines explicitly state: "Retinopathy status should be assessed when intensifying glucose-lowering therapies such as those using GLP-1 RAs, since rapid reductions in A1C can be associated with initial worsening of retinopathy" 2. However, guidelines emphasize that long-term glycemic control benefits outweigh acute risks 3.

Critical Nuances

The evidence presents an important paradox: While semaglutide can acutely worsen retinopathy through rapid glucose reduction, long-term glycemic control ultimately protects against retinopathy progression 2. The 2022 Canadian guidelines note: "The long-term benefits of glucose control on the eyes far outweigh any acute risk" 3.

Distinguishing from aspirin: Unlike concerns about antiplatelet therapy, aspirin does NOT increase retinal hemorrhage risk and should not be discontinued 6, 7, 8. This is an important clinical distinction.

Formulation matters: Subcutaneous semaglutide shows higher reporting rates for retinal complications compared to oral formulations, though both carry risk 5.

Common Pitfalls to Avoid

  • Don't skip baseline eye exams - The absolute risk increase is 3-fold higher in patients with pre-existing retinopathy who aren't being monitored 1
  • Don't confuse correlation with contraindication - Pre-existing retinopathy is NOT a contraindication to semaglutide; it's an indication for closer monitoring 2, 3
  • Don't attribute all retinal hemorrhage to the drug - Diabetic retinopathy naturally progresses; the drug may accelerate existing disease rather than cause de novo hemorrhage in patients without diabetes-related eye disease
  • Don't discontinue without ophthalmology input - If retinopathy worsens, coordinate with ophthalmology for potential laser photocoagulation or anti-VEGF therapy rather than automatically stopping a medication with proven cardiovascular mortality benefit 2, 1

Bottom line for practice: Ozempic can cause retinal hemorrhage as part of diabetic retinopathy complications. Screen eyes before starting, monitor vision during treatment, and increase ophthalmology surveillance in patients with baseline retinopathy—but don't withhold this cardiovascular-protective medication based solely on retinopathy presence.

Related Questions

What is the evidence for vision loss associated with semaglutide?
What are the long-term negative effects of GLP-1 (Glucagon-Like Peptide-1) receptor agonists, such as semaglutide (Ozempic) or liraglutide (Victoza), in patients with type 2 diabetes?
Can I administer a 0.25 mg dose using a 1 mg pen of Ozempic (semaglutide)?
Can I take hyoscine (scopolamine) with Wegovy (semaglutide)?
In a patient on oral semaglutide (Rybelsus) who progressed from 3 mg to 7 mg (weight loss from 103 kg to 93 kg) and then to 14 mg, will additional weight loss be expected, does the higher dose increase the risk of ocular complications such as worsening diabetic retinopathy, and if the patient must revert to 7 mg, how likely is weight regain?
Are vestibular rehabilitation exercises (e.g., Epley maneuver, Semont maneuver, Brandt‑Daroff exercises, gaze‑stabilization drills) safe to perform at 21 weeks gestation?
What are the recommended starting and maintenance doses of furosemide (loop diuretic) for adults, including oral and intravenous routes and adjustments for renal impairment, elderly patients, or hepatic dysfunction?
What is the recommended regimen for using Efudix (5‑fluorouracil) cream to treat squamous cell carcinoma in situ on the scalp?
How many cycles of R‑CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy are recommended for diffuse large B‑cell lymphoma?
How should I evaluate and manage a patient with a lifelong history of frequent illness, no diagnosed autoimmune disease, presenting with IBS‑type symptoms and new‑onset decreased libido?
What is the Malin’s Intelligence Scale for Indian Children (MISIC) and how is it used in psychiatric assessment of Indian children?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.